Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Oncology"
DOI: 10.3892/ijo.2020.5103
Abstract: Lung cancer has the highest incidence and mortality rates among the malignant tumor types world-wide. Platinum-based chemotherapy is the main treatment for advanced non-small-cell lung cancer (NSCLC), and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)… read more here.
Keywords: gefitinib cisplatin; gefitinib; cisplatin nsclc; inhibition dna ... See more keywords